2017 Press Releases

Keyword Search
 
2017 | 2016
DateTitle 
09/25/17Pulse Biosciences Announces $30 Million Private Placement
HAYWARD, Calif.--(BUSINESS WIRE)--Sep. 25, 2017-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, today announced that it has entered into a stock purchase agreement with Robert W. Duggan, an accredited investor and experienced life sciences executive, for the purchase of 2,000,000 shares of the Company’s common stock at a price o... 
Printer Friendly Version
09/11/17Pulse Biosciences Announces Withdrawal and Planned Resubmission of 510(k) Application for the PulseTxTM System
HAYWARD, Calif.--(BUSINESS WIRE)--Sep. 11, 2017-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that it has withdrawn its initial application to the United States Food and Drug Administration (FDA) for 510(k) clearance of its PulseTxTM System. The voluntary withdrawal on September 8, 2017, was the ... 
Printer Friendly Version
07/27/17Pulse Biosciences Quarterly Investor and Analyst Conference Call
Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT HAYWARD, Calif.--(BUSINESS WIRE)--Jul. 27, 2017-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform today reports recent corporate developments and financial results for the quarter ended June 30, 2017. Recent Developments Initiation... 
Printer Friendly Version
07/11/17Pulse Biosciences to Host Quarterly Investor Conference Call on July 27, 2017
BURLINGAME, Calif.--(BUSINESS WIRE)--Jul. 11, 2017-- Pulse Biosciences, Inc., (Nasdaq: PLSE) a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), will host its quarterly investor conference call on July 27, 2017, at 1:30 p.m. PDT / 4:30 p.m. EDT. The company will provide an update on the clinical advancement of the PulseTxTM System, including progress of the clinical study eval... 
Printer Friendly Version
06/06/17Pulse Biosciences Announces Treatment of First Patient in Study to Evaluate the Safety and Efficacy of Novel Nano-Pulse Stimulation Technology for Seborrheic Keratosis Lesions
BURLINGAME, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a therapeutic tissue treatment platform based on its proprietary Nano-Pulse Stimulation (NPS) technology, today announced treatment of the first patient in the Company's multi-center study evaluating the safety and efficacy of the NPS technology for the treatment of seborrheic keratosis (SK). SK is one of the most common types of skin lesions, impacting over 80 million patients in ... 
Printer Friendly Version
05/04/17Pulse Biosciences Quarterly Investor Conference Call
Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif.--(BUSINESS WIRE)--May 4, 2017-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), is hosting an investor conference call today to share information on recent developments and progress for its novel NPS platform. The Company will also provide financia... 
Printer Friendly Version
04/17/17Pulse Biosciences to Host Quarterly Investor Conference Call on May 4, 2017
BURLINGAME, Calif.--(BUSINESS WIRE)--Apr. 17, 2017-- Pulse Biosciences, Inc., (Nasdaq: PLSE) a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), will host its quarterly investor conference call on May 4, 2017, at 1:30 p.m. PDT / 4:30 p.m. EDT. The company will highlight its 2017 progress to-date on the NPS clinical programs underway and discuss developments related to the Puls... 
Printer Friendly Version
03/14/17Pulse Biosciences Quartery Investor Conference Call
Investor conference call today at 1:30 p.m. PDT / 4:30 p.m. EDT BURLINGAME, Calif.--(BUSINESS WIRE)--Mar. 14, 2017-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), is hosting an investor conference call today to share information on recent developments and progress for its novel NPS platform in key markets. The Company will also ... 
Printer Friendly Version
03/14/17Pulse Biosciences Submits 510(k) Application to FDA for PulseTx™ System
BURLINGAME, Calif.--(BUSINESS WIRE)--Mar. 14, 2017-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), today announced the submission of a 510(k) to the US Food and Drug Administration for its PulseTx™ System. NPS is a non-thermal drug-free tissue treatment technology that can stimulate unique behaviors in cells by applying ultr... 
Printer Friendly Version
03/01/17Pulse Biosciences to Host Investor Conference Call on March 14, 2017
BURLINGAME, Calif.--(BUSINESS WIRE)--Mar. 1, 2017-- Pulse Biosciences, Inc., (Nasdaq: PLSE) a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), will host its first quarter investor conference call on March 14, 2017, at 1:30 p.m. PDT / 4:30 p.m. EDT. The company will highlight progress to-date on its NPS clinical programs, PulseTx System development, as well as provide an updat... 
Printer Friendly Version
02/10/17Pulse Biosciences Announces Healthcare Executives and Entrepreneurs Robert Duggan and Dr. Maky Zanganeh Have Acquired a Combined Interest of 17.1% of the Company
Company Appoints Dr. Maky Zanganeh to Company Board of Directors BURLINGAME, Calif.--(BUSINESS WIRE)--Feb. 10, 2017-- Pulse Biosciences, Inc. (Nasdaq:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment platform based on Nano-Pulse Stimulation (NPS), today announced that Robert “Bob” Duggan and Maky Zanganeh, the former CEO and COO of Pharmacyclics Inc. (now Pharmacyclics LLC, a wholly owned subsidiary of AbbVie I... 
Printer Friendly Version